Cancer Liver

Posts Tagged ‘China’

MORE INFO @ LloydWright.org selenium http

Product Description
This econometric study covers the latent demand outlook for liver cancer drugs across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang – Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as “regions”). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in Greater China. For each major city in question, the percent share the city is of the region and of Greater China is reported. Each major city is defined as an area of “economic population”, as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this “economic” definition of population, comparative benchmarks allow the reader to quickly gauge a city’s marketing and distribution value vis-a-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for liver cancer drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or

The 2011-2016 Outlook for Liver Cancer Drugs in Greater China

AMC, acclaimed for both clinical and research achievements and experience in liver cancer treatment, was selected to serve as Asias first Continent Liver Cancer Medical Education Center. Physicians and staffers dealing with liver cancer treatment from the Departments of General Internal Medicine, Surgery and Radiology invited liver cancer specialists from across Asia and held PATH (Program for the Advancement of Therapy in Hepatocellular Carcinoma) to introduce AMCs advanced treatment systems and share ideas on better treatment options. The program was carried out in 8 sessions for 3 days, bringing together 20 liver disease experts from China, India and Thailand and training them on cutting-edge liver cancer treatment plans offered by AMC. For the duration of the program, international physicians took a tour around operating rooms and observed radiotherapy procedures carried out in the Angiography Room of the Department of Radiology. This designation of a PATH education center is the fourth worldwide and the first in Asia. It is expected to provide momentum for AMC to strengthen its presence and promote its superior medical technologies in the global market.

We have located the best hospital in China for foreign advanced-cancer patients to be treated with a combination of gene therapy (Gendicine), immunotherapy (CIK or DC-CIK biotherapy), Cancer Stem Cell Targeted Treatment, a powerful anti-angiogenosis drug (Endostar), mild chemotherapy, HIFU non-invasive or Croysurgery minimal invasive surgery and traditional Chinese medicine (herb). This combined treatment is only available at the Beijing GreatWall International Cancer Center (BGWICC). It is very effective for pancreatic cancer, lung cancer, ovarian cancer,kidney cancer, prostate cancer, colorectal cancer, liver cancer, and breast cancer and it has very little or no side effects. BGWICC has successfully treated patients suffering from a number of advanced cancers with very encouraging results of more than 65% effective rate for liver, lung, pancreas, colorecta, ovary, breast cancer and relative metastasis. Patients include overseas patients from Turkey, Netherland, Australia, US, Canada, Germany, Britain and Singapore. Many patients had already failed to respond to varieties of chemotherapy regimens when they came and they achieve impressive efficacies here in BGWICC. For us …… Web: www.celltherapybeijing.com Patient Service Office Eel:(0086-10)51520752 Email: info@bgwicc.com

In this video, Hans Rosling uses liver cancer statistics to show how cancer data from IARC ( International Agency for research on Cancer) can be displayed as moving bubbles in Gapminder World. In this visual way, you can easily compare data for the most common cancers and rapidly understand that each of them have different distributions in the world. Liver cancer is mainly caused by chronic infection by the Hepatitis B virus (and also by the Hepatitis C virus). As this infection is most common in China and other parts of East Asia, as well as in Africa South of the Sahara, it is the countries in these regions that bear the main burden of Liver Cancer in the World (independent of if they have low, middle or high income). Comparing gender differences indicate that higher alcohol consumption in men may explain why the rate of liver cancer in men is twice as high as in women. is.gd – New cases of liver cancer per 100 000 men (with size showing the total number of new cases of liver cancer)